TEL AVIV, Israel, April 3, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) is pleased to announce that it received the final report of the research held in the Technion Israel Institute of Technology, in which the antitumor activity of cannabinoids was reflected in several types of cancer (breast, ovarian, colon, pancreatic, gastric, glioblastoma).
The results which were obtained, using High Throughput Screening technology (HTS), clearly indicate that the company's cannabinoid compounds caused apoptosis (programed cancer cell death) in all cancer types mentioned above with no effect on healthy normal cells.
These results pave the way for a possible antitumor treatment which the company will further examine. Moreover, the differential efficacy of different cannabinoids emphasizes the need for personalized diagnostics - and the data obtained serves this purpose.
Itamar Borochov, CEO of Cannabics Pharmaceuticals said, "The results from this research strengthen our vision of creating anticancer treatments based on natural cannabis medicine".
About Cannabics Pharmaceuticals Inc.
Cannabics Pharmaceuticals Inc. (CNBX), a U.S-based public company, is dedicated to the development of personalized anti-cancer and palliative treatments. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company's focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics engages in developing individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-K/A Report filed on March 15, 2017. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
For further information, please contact:
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-inc-receives-the-final-report-of-its-research-on-antitumor-properties-of-cannabinoids-held-in-israel-300433741.html